Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AHPA Stock Forecast 2026-2027
$1.99
Current Price
$45.77M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AHPA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
AHPA Price Momentum
+5.3%
1 Week Change
+17.1%
1 Month Change
-38.0%
1 Year Change
+7.6%
Year-to-Date Change
-42.4%
From 52W High of $3.46
+63.1%
From 52W Low of $1.22
📊 TOP ANALYST CALLS
Did AHPA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Avista II is one of their latest high-conviction picks.
Latest AHPA Stock Price Targets & Analyst Predictions
AHPA has shown a year-to-date change of 7.6% and a 1-year change of -38.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for AHPA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AHPA Analyst Ratings
0
Buy
0
Hold
0
Sell
AHPA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.99
Latest AHPA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AHPA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Avista Public Acquisition Corp. II (AHPA) Competitors
The following stocks are similar to Avista II based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Avista Public Acquisition Corp. II (AHPA) Financial Data
Valuation Metrics
Market Cap
$45.77M
Enterprise Value
$0
P/E Ratio
N/A
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.3%
Current Ratio
0.1x
Debt/Equity
0.0x
ROE
N/A
ROA
N/A
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Avista Public Acquisition Corp. II (AHPA) Business Model
Avista Public Acquisition Corp. II (AHPA) Latest News & Analysis
Latest News
Quick Summary
No relevant financial information is provided in the excerpt from Emeryville, California. Further details are needed for investor insights.
Why It Matters
The location indicates potential market developments or strategic moves by companies in Emeryville, which could impact local economies and investment opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
APAC shareholders have approved the business combination with OmniAb, signaling a significant step forward for the company.
Why It Matters
The approval of the OmniAb business combination by APAC shareholders signals potential growth and strategic alignment, impacting stock performance and future investment opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Ligand announced that Janssen received U.S. FDA approval for TECVAYLI™ (teclistamab), a significant development for the company's portfolio.
Why It Matters
FDA approval for TECVAYLI™ boosts Ligand's partnership value with Janssen, potentially increasing revenue and market confidence, impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Avista Public Acquisition Corp. II (NASDAQ: AHPA) will hold a shareholder meeting on October 24, 2022, to vote on its proposed business combination with OmniAb, Inc.
Why It Matters
The upcoming vote on the business combination between APAC and OmniAb could significantly impact stock performance and investor sentiment, influencing market dynamics and future valuations.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Ligand Pharmaceuticals has announced the record date and details for the distribution related to its spin-off of OmniAb.
Why It Matters
The announcement of a record date for Ligand's OmniAb spin-off signals potential value creation and investment opportunities, affecting share prices and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Ligand Pharmaceuticals reported its financial results for the second quarter of 2022.
Why It Matters
Ligand's Q2 2022 financial results provide insights into its performance, impacting stock valuation and investor sentiment. Earnings reports can influence market reactions and investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About AHPA Stock
What is Avista Public Acquisition Corp. II's (AHPA) stock forecast for 2026?
Analyst forecasts for Avista Public Acquisition Corp. II (AHPA) are not currently available. The stock is trading at $1.99.
Is AHPA stock a good investment in 2026?
Analyst ratings for AHPA are not currently available. The stock is currently trading at $1.99. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AHPA stock?
Price predictions from Wall Street analysts for AHPA are not currently available. The stock is trading at $1.99.
What is Avista Public Acquisition Corp. II's business model?
N/A
What is the highest forecasted price for AHPA Avista Public Acquisition Corp. II?
Price targets from Wall Street analysts for AHPA are not currently available. The stock is trading at $1.99.
What is the lowest forecasted price for AHPA Avista Public Acquisition Corp. II?
Price targets from Wall Street analysts for AHPA are not currently available. The stock is trading at $1.99.
What is the overall AHPA consensus from analysts for Avista Public Acquisition Corp. II?
Analyst ratings for AHPA are not currently available. The stock is trading at $1.99.
How accurate are AHPA stock price projections?
Stock price projections, including those for Avista Public Acquisition Corp. II, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 6:02 AM UTC